iBio, Inc. (OTCBB:IBPM) is a biopharmaceutical company focused on the development and commercialization of novel plant-made products for the prevention and treatment of serious infectious diseases.

We have a pipeline of proprietary products in preclinical development, including:

• Sub-unit vaccines directed against both seasonal and pandemic influenza
• Sub-unit vaccines for prevention of anthrax and plague
• Sub-unit vaccines for treatment of HPV infections
• Therapeutic antibodies for treatment of anthrax
• Antibodies for prevention, treatment and diagnosis of pandemic influenza

We have developed iBioLaunch™, a platform technology for accelerated discovery and production of improved vaccines, monoclonal antibodies and therapeutic proteins. This unique plant-based platform offers a number of significant advantages over conventional production systems:

• Very large scale protein production capacity
• Greatly reduced capital requirements
• Short production timeframes
• Ability to synthesize complex proteins of high quality
• Low risk of contamination by animal pathogens